Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced or Metastatic Solid Tumors: early-phase trial registry
11 of 20 indexed Advanced or Metastatic Solid Tumors trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 11 currently recruiting · #848 of 28,707 conditions by registered trial count
Advanced or Metastatic Solid Tumors: 20 US clinical trials tracked, 11 recruiting.
Advanced or Metastatic Solid Tumors is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most active sponsor is Erasca, running 3 of these trials.
Enrollment posture brief
Registry condition advanced-or-metastatic-solid-tumors
OPEN 11 | RECR 55% | LATE 0 | EARLY 20 | RANK #848 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Recurrent Endometrial Carcinoma (55% recruiting · 20 trials)
Advanced or Metastatic Solid Tumors lists 11 open slots (55% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced or Metastatic Solid Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced or Metastatic Solid Tumors is recruiting above its size-band peers.
11 of 20 indexed trials (55%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Advanced or Metastatic Solid Tumors research.
Erasca accounts for 3 of 20 trials (15%). 15 distinct sponsors appear on at least one study for this condition label.
-
Typical Advanced or Metastatic Solid Tumors enrolment sits around 200 participants.
Median target enrolment is 200 among the 20 trials that report a genuine target (sentinel values excluded). 4 of those (20%) plan for fewer than 100 participants.
-
Advanced or Metastatic Solid Tumors research is mostly interventional.
20 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
DynamiCure Biotechnology
NCT05785754
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
NCT06724016
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
Incendia Therapeutics
NCT05753722
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
Day One Biopharmaceuticals
NCT06752681
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
NCT06234397
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Takeda
NCT07205718
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
NCT05787587
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Innate Pharma
NCT06781983
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NextCure
NCT06774963
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
NCT05538130
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
858 Therapeutics
NCT06395519
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
Erasca
NCT04670679
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
Erasca
NCT04866134
A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma
Werewolf Therapeutics
NCT06939283
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
NextCure
NCT05572684
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
Erasca
NCT05907304
A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Tallac Therapeutics
NCT05399654
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
Merck Sharp & Dohme
NCT05382325
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
NCT01928394
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
Takeda
NCT04381650
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 20 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced or Metastatic Solid Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced or Metastatic Solid Tumors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced or Metastatic Solid Tumors page
20 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Advanced or Metastatic Solid Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Erasca sponsors the most Advanced or Metastatic Solid Tumors trials on record, review their full trial history before evaluating a specific study. See Erasca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced or Metastatic Solid Tumors condition card totals 20 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.